Skip to Main Content

Author Details

Barbara Hutter
National Center for Tumor Diseases (NCT) Heidelberg
2006
62
29
PMIDPaper TitleJournal TitlePublished Year
36702933Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers.Nat Cancer2023
37884744NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology.NPJ Precis Oncol2023
36702933Comprehensive analysis of mutational signatures reveals distinct patterns and molecular processes across 27 pediatric cancers.Nat Cancer2023
36470093Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study.Eur J Cancer2023
37884744NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology.NPJ Precis Oncol2023
36470093Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study.Eur J Cancer2023
34045664Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.Cancer Gene Ther2022
35918329Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.Nat Commun2022
36481818Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer.Nat Commun2022
34045664Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies.Cancer Gene Ther2022
36481818Author Correction: Genomic footprints of activated telomere maintenance mechanisms in cancer.Nat Commun2022
35918329Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.Nat Commun2022
32949162Integrating proteomics into precision oncology.Int J Cancer2021
34112699Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.Cancer Discov2021
34036222CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.JCO Precis Oncol2021
33441414Accurate and efficient detection of gene fusions from RNA sequencing data.Genome Res2021
34250401Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With <i>ETV6-NTRK3</i> Fusion-Positive Carcinoma Harboring the <i>NTRK3</i> <sup>G623R</sup> Solvent-Front Mutation.JCO Precis Oncol2021
34185311High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.Br J Dermatol2021
32949162Integrating proteomics into precision oncology.Int J Cancer2021
34785797Publisher Correction: Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia.Leukemia2021
34808524Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.ESMO Open2021
34785797Publisher Correction: Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia.Leukemia2021
34808524Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial.ESMO Open2021
34185311High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinoma.Br J Dermatol2021
34250401Response to Cabozantinib Following Acquired Entrectinib Resistance in a Patient With <i>ETV6-NTRK3</i> Fusion-Positive Carcinoma Harboring the <i>NTRK3</i> <sup>G623R</sup> Solvent-Front Mutation.JCO Precis Oncol2021
34036222CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer.JCO Precis Oncol2021
34112699Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers.Cancer Discov2021
33441414Accurate and efficient detection of gene fusions from RNA sequencing data.Genome Res2021
31558800Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains.Oncogene2020
35846099Ruxolitinib is effective in the treatment of a patient with refractory T-ALL.EJHaem2020
32024817Genomic footprints of activated telomere maintenance mechanisms in cancer.Nat Commun2020
32017710Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.J Clin Invest2020
32127638Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia.Leukemia2020
31558800Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains.Oncogene2020
32156527Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease.Pancreatology2020
32385320The landscape of chromothripsis across adult cancer types.Nat Commun2020
33028839Framework for quality assessment of whole genome cancer sequences.Nat Commun2020
32843432Successful BRAF/MEK inhibition in a patient with <i>BRAF</i><sup>V600E</sup>-mutated extrapancreatic acinar cell carcinoma.Cold Spring Harb Mol Case Stud2020
32501622Germline SDHB-inactivating mutation in gastric spindle cell sarcoma.Genes Chromosomes Cancer2020
35846099Ruxolitinib is effective in the treatment of a patient with refractory T-ALL.EJHaem2020
32024817Genomic footprints of activated telomere maintenance mechanisms in cancer.Nat Commun2020
32017710Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.J Clin Invest2020
33028839Framework for quality assessment of whole genome cancer sequences.Nat Commun2020
32843432Successful BRAF/MEK inhibition in a patient with <i>BRAF</i><sup>V600E</sup>-mutated extrapancreatic acinar cell carcinoma.Cold Spring Harb Mol Case Stud2020
32501622Germline SDHB-inactivating mutation in gastric spindle cell sarcoma.Genes Chromosomes Cancer2020
32385320The landscape of chromothripsis across adult cancer types.Nat Commun2020
32127638Comprehensive genomic characterization of gene therapy-induced T-cell acute lymphoblastic leukemia.Leukemia2020
32156527Metastatic adult pancreatoblastoma: Multimodal treatment and molecular characterization of a very rare disease.Pancreatology2020
31138115TelomereHunter - in silico estimation of telomere content and composition from cancer genomes.BMC Bioinformatics2019
31138115TelomereHunter - in silico estimation of telomere content and composition from cancer genomes.BMC Bioinformatics2019
  • 1 - 50 of 124

Recommended Authors

Instituto Universitario de Oncologia (IUOPA), Universidad de Oviedo
Career Start Year 2018
Number of shared co-authors 20
The Hong Kong University of Science and Technology
Career Start Year 2012
Number of shared co-authors 2
The Hospital for Sick Children
Career Start Year 2012
Number of shared co-authors 23
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 15
Van Andel Institute
Career Start Year 2010
Number of shared co-authors 13
Wellcome Sanger Institute
Career Start Year 2009
Number of shared co-authors 2
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 23
McGill University
Career Start Year 2006
Number of shared co-authors 12
Manchester Cancer Research Centre, University of Manchester
Career Start Year 2006
Number of shared co-authors 26
German Cancer Research Center (DKFZ)
Career Start Year 2006
Number of shared co-authors 42
H. Lee Moffitt Cancer Center and Research Institute
Career Start Year 2005
Number of shared co-authors 1
Broad Institute of MIT and Harvard
Career Start Year 2004
Number of shared co-authors 27
Roswell Park Comprehensive Cancer Center
Career Start Year 2003
Number of shared co-authors 0
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 16
McDonnell Genome Institute, Washington University in St. Louis
Career Start Year 2003
Number of shared co-authors 11
The Francis Crick Institute
Career Start Year 2003
Number of shared co-authors 22
University of California
Career Start Year 2003
Number of shared co-authors 4
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 10
Center for Immunotherapy and Precision-Immuno-Oncology, Cleveland Clinic
Career Start Year 2001
Number of shared co-authors 0
Broad Institute of the Massachusetts Institute of Technology and Harvard
Career Start Year 2000
Number of shared co-authors 45
Institute for Translational Epigenetics, University of Cologne
Career Start Year 1999
Number of shared co-authors 14
Early Cancer Institute, University of Cambridge
Career Start Year 1999
Number of shared co-authors 24
From Foundation Medicine
Career Start Year 1999
Number of shared co-authors 0
St. Jude Children's Research Hospital
Career Start Year 1999
Number of shared co-authors 11
Universitat Pompeu Fabra
Career Start Year 1999
Number of shared co-authors 33
The Broad Institute of Harvard and MIT
Career Start Year 1998
Number of shared co-authors 17
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 27
The University of Texas MD Anderson Cancer Center
Career Start Year 1995
Number of shared co-authors 5
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1994
Number of shared co-authors 19
The University of Texas MD Anderson Cancer Center
Career Start Year 1991
Number of shared co-authors 21

Collaborators

German Cancer Research Center (DKFZ)
Co-authored papers 46
German Cancer Research Center (DKFZ), National Center for Tumor Diseases (NCT)
Co-authored papers 36
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 24
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 22
National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ)
Co-authored papers 20
Berlin Institute of Health at Charite-Universitatsmedizin Berlin
Co-authored papers 18
Co-authored papers 17
Berlin Institute of Health (BIH) and Charite
Co-authored papers 17
University of Augsburg
Co-authored papers 16
Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM)
Co-authored papers 15
German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT)
Co-authored papers 14
German Cancer Research Center (DKFZ)
Co-authored papers 12
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 11
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 11
German Cancer Research Center (DKFZ)
Co-authored papers 9
Co-authored papers 9
Co-authored papers 9
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 8
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 8
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 7
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 7
Co-authored papers 7
German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK)
Co-authored papers 7
St Jude Children's Research Hospital
Co-authored papers 7
Institute of Pathology, University Hospital Heidelberg
Co-authored papers 6
Co-authored papers 6
Max Planck Institute for Molecular Genetics
Co-authored papers 5
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 5
European Bioinformatics Institute (EMBL-EBI)
Co-authored papers 5
University of Copenhagen
Co-authored papers 5